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Mechanisms of Therapeutic Resistance in Prostate Cancer
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40536, USA
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Abstract
Abstract Prostate cancer is the second leading cause of cancer deaths in the USA. The challenge in 
managing castration-resistant prostate cancer (CRPC) stems not from the lack of therapeutic 
options but from the limited duration of clinical and survival benefit offered by treatments in this 
setting due to primary and acquired resistance. The remarkable molecular heterogeneity and tumor 
adaptability in advanced prostate cancer necessitate optimization of such treatment strategies. 
While the future of CRPC management will involve newer targeted therapies in deliberately 
biomarker-selected patients, interventions using current approaches may exhibit improved clinical 
benefit if employed in the context of optimal sequencing and combinations. This review outlines 
our current understanding of mechanisms of therapeutic resistance in progression to and after the 
development of castration resistance, highlighting targetable and reversible mechanisms of 
resistance.
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Introduction
In 2016, there will be over 180,000 new cases of prostate cancer in the USA alone, 
accounting for over one in five new cancer diagnoses [1]. While it is also a leading cause of 
cancer deaths, prostate cancer patients display a wide spectrum of clinical trajectories and 
outcomes, where some achieve remission yet others rapidly develop lethal disease. Our 
understanding of the use of systemic therapies to impair prostate tumor growth stems from 
Huggins’ seminal discovery in 1941 on the therapeutic response of prostate cancer to 
castration-induced androgen deprivation [2], groundbreaking work which led to his receipt 
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of the Nobel Prize in 1966. Since then, while we have amassed more knowledge on the 
intricacies of androgen signaling axis and the androgen receptor (AR), the treatment 
paradigm for recurrent and advanced prostate cancer, as well as an adjuvant to localized 
prostate cancer, remains dependent on androgen deprivation in the form of surgical or 
medical castration, the latter via an approach known as androgen deprivation therapy (ADT) 
[3]. Today, ADT is deployed for men with both metastatic and high-risk localized diseases 
and is frequently utilized alongside other modalities.
First-line ADT, most frequently administered in the form of luteinizing hormone-releasing 
hormone (LHRH) agonists/antagonists with or without antiandrogens, suppresses prostate-
specific antigen (PSA) levels in up to 90% of patients whose disease has spread beyond the 
prostate [4]. While dramatic initial responses to ADT are not uncommon, these responses 
are seldom sustained in the long term, with the median duration of response of up to 
18months [5]. Virtually, all patients eventually progress to castration resistance, during 
which biochemical and radiographic progression is observed despite castrate levels of serum 
testosterone [6]. This key characteristic of continued tumor progression despite seemingly 
“starved” androgen conditions led to the initial impression that castration-resistant prostate 
cancer (CRPC) was a hormone-independent entity. The realization that CRPC remains 
fueled by androgen signaling, albeit with an increased utility of nontraditional pathways and 
alterations involving both the androgenic ligand (dihydrotestosterone (DHT)) and the AR 
[7], led to newer AR-directed agents abiraterone and enzalutamide deployed in metastatic 
CRPC (mCRPC) that are direct efficacious strategies targeting the continued dependence of 
prostate cancer on androgens [8, 9]. These therapeutic manipulations, however, are also met 
with resistance which remains an issue in the second-, third-, and fourth-line therapies—or 
until the patient finally succumbs to his illness. Today, the median overall survival for 
patients upon developing CRPC is in the range of 14–26 months [10].
Considering the augmentation of FDA-approved options for men with CRPC from only 
docetaxel in 2004 to six [8, 9, 11–14] different therapies in 2016, there is great need to 
understand the selective pressures that drive resistance to identify actionable targets that 
prolong the duration of benefit offered by these treatments. In addition, questions 
surrounding optimal treatment sequencing and combinations remain [15, 16] and are 
currently being examined by both prospective and retrospective studies. Indeed, the issue of 
resistance extends beyond patients developing refractory disease to continued therapy with 
one agent to other agents in the form of cross-resistance occurring not only in the context of 
drugs targeting the same pathway but also between drug classes [17–19]. With newer 
treatments in the developmental pipeline, we are faced with a rapidly evolving clinical 
landscape but a lagging understanding of how each treatment complements another and their 
sequencing optimization platforms to maximize clinical efficacy. This review will examine 
the known pathways of therapeutic resistance to systemic therapies, focusing on potentially 
targetable resistance reversal strategies in advanced lethal CRPC.
Resistance to Androgen Ablation in Hormone-Sensitive Disease
Resistance to ADT is virtually inevitable but occurs after a unique timeline of therapy for 
each patient after biochemical recurrence or diagnosis of advanced disease [20]. The clinical 
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heterogeneity in progression to metastatic CRPC reflects the diversity of molecular 
adaptations present in this setting. The deprivation of serum testosterone initially leads to 
reduced levels of DHT, the primary mediator of AR signaling in prostate tissue. Upon 
withdrawal of these ligands, the androgen-dependent tumor cells undergo dramatic 
apoptosis, while a subset may maintain a dormant state [21]. Cancer stem cells have also 
been appreciated in this setting in promoting progression to CRPC [22]. Eventually, a 
population of such arrested cells is able to adapt to these states of low androgen, resuming 
proliferation with progression manifesting in the form of rising PSA that may or may not be 
coupled with osseous, soft tissue, or visceral metastases [23]. Progression to CRPC thus 
represents a cumulation of resistance strategies deployed by cells against castration. These 
critical adaptations involving the AR, ligand, as well as signaling regulators of the AR 
mechanistic pathway are described in the following sections (and illustrated in Fig. 1).
AR Adaptations Towards Alternative Activation Mechanisms
Among the strategies deployed by tumor cells to evade apoptosis induction by ADT, several 
mechanisms fall under functional adaptations of AR actions. One of the earlier 
breakthroughs in understanding the development of hormone-refractory disease came with 
the observation of AR gene amplification [24, 25], detected in almost a quarter of CRPC 
tissue specimens but virtually nonexistent in hormone-sensitive tissue [26]. In addition, 
studies have shown that resistance to antiandrogens is consistently linked to upregulation of 
AR expression [27], reflecting adaptations to increase sensitivity to low androgen (ligand) 
levels in sustaining AR programs (Fig. 1(A)). Antiandrogens used in combined androgen 
blockade in hormone-sensitive disease traditionally utilize bicalutamide, and less commonly 
flutamide and nilutamide. An important observation in this setting was that 15–30% [28] of 
tumors, upon becoming resistant to androgen blockade, would exhibit regressions after 
discontinuation of therapy, a phenomenon clinically defined as antiandrogen withdrawal 
syndrome (AWS) [29]. Now, we appreciate that certain AR mutations are well known to 
reactivate AR signaling; the T877A mutation, for example, confers resistance to 
hydroxyflutamide, the active form of flutamide [30]. W741C/L, another mutation of the AR 
ligand binding domain (LBD), confers resistance to bicalutamide [31], both of which 
illustrate the molecular basis of AWS. Additionally, the previously mentioned T877A 
mutation coupled with another AR mutation L701H functionally confers a promiscuous 
activation of the AR by glucocorticoids [32] (Fig. 1(B)). Comparisons between AR-
dependent target genes in androgen-independent and androgen-dependent cells reveal that 
the AR-regulated transcriptional program is notably altered in castration-resistant disease, 
especially in the context of cell cycle genes, some of which result in the inactivation of cell 
cycle checkpoints [33].
AR activities can be stimulated by alternative signaling pathways, many of which play 
significant roles in the development of other human malignancies [34]. The NF-κB 
transcription factor signaling pathway has an established role in the progression to CRPC by 
maintaining AR activity [35] and sustaining AR messenger RNA (mRNA) and protein 
expression levels [36]. Further, its gene signature is sufficient in predicting prostate cancer-
specific survival in clinical samples [37]. Other prominent survival signaling pathways 
(bypassing AR-driven mechanisms) such as the PI3K/AKT pathway have also been 
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examined in the context of progression to metastatic CRPC and established as contributors 
to advanced metastatic disease [38]. The loss of phosphatase and tensin homolog deleted on 
chromosome ten (PTEN), tumor suppressor, and negative regulator of this pathway is one of 
the most frequent of molecular alterations in human prostate cancer. Indeed, PTEN loss 
allows the promotion of growth independent of AR signaling, and given PTEN loss, the 
development of castration resistance is intrinsic and not contingent on sustained AR activity 
[39, 40]. Further, PTEN status at diagnosis is predictive of not only time to CRPC, 
metastasis, and prostate cancer-specific survival but also response to ADT [41]. Finally, 
growth factors including insulin-like growth factor 1 (IGF-1), keratinocyte growth factor 
(KGF), and epidermal growth factor (EGF) have been shown to directly activate AR 
independent of androgen [42]. A schematic representation of these pathways is depicted in 
Fig. 1(C).
The AR is known to interact with a plethora of coactivators and corepressors (over 150) 
[43], many of which play a role in the transition to castration-resistant disease. Co-activators 
enhancing AR activity may functionally contribute to the AR’s heightened sensitivity to 
alternative ligands in the absence of endogenous androgen [44]. For example, the coactivator 
ARA70 can increase AR responsiveness to estradiol in prostate cancer cell lines [45] (Fig. 
1(B)). FKBP51, another coactivator, stabilizes the HSP90-AR complex, enhancing the 
ability of AR molecules to bind to androgen [46]. Finally, TRIM24 is a transcriptional 
activator that has been shown to contribute to AR signaling under castrate androgen levels in 
SPOP mutants and in CRPC [47] (Fig. 1(D)).
Ligand Synthesis Adaptations
Castration-induced androgen withdrawal is known to deplete levels of circulating 
testosterone by 90–95% and achieve castrate levels of serum testosterone (less than 20 
ng/dL) in most patients [48]; however, there is evidence to suggest that intratumoral levels of 
DHT in prostate tissue remain around 25% and could be as high as 40% of baseline prior to 
therapy [49]. These levels of intratumoral androgen are sufficient to sustain androgen 
signaling [50, 51] and can be accounted for in part by the contribution of androgen 
precursors from the adrenal gland, namely dehydroepiandrosterone (DHEA) and DHEA-S, 
its sulfated form. DHEA can be converted to DHT within the tumor via enzymes 3β-
hydroxysteroid dehydrogenase (3βHSD), steroid 5α-reductase (SRD5A), and 17β-
hydroxysteroid dehydrogenase (17βHSD) [52]. Emergence of prostate cancer cells to a 
castration-resistant state involves the upregulation of various steroidogenic enzymes, 
including HSD3B1, HSD3B2, HSD17B3, SRD5A1, and CYP17A1 for higher production of 
intratumoral androgen [53, 54]. A gain of function mutation has been identified in 3βHSD, 
conferring resistance to ubiquitination and degradation [55]. From a clinical standpoint, the 
efficacy of cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17), inhibiting agents 
abiraterone and now the less commonly used ketoconazole, is reflective of the dependence 
of CRPC on androgen metabolism [56]. Moreover, other nontraditional pathways for DHT 
synthesis that can bypass biochemical synthesis of testosterone utilize precursors such as 
acetic acid and progesterone [57]. A schematic representation of these pathways is shown in 
Fig. 1(E).
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Impact of the Prostate Tumor Microenvironment: Can Epithelial-Mesenchymal Transition 
Circumvent Apoptosis?
While there have been significant molecular advances in genomic classification of human 
cancer during disease progression to metastasis, our understanding of the biology of 
individual tumors as an independent phenotypic entity is still profoundly limited; tumor 
behavior and biological properties depend largely on cancer epithelial cells and the adjacent 
stromal cells that comprise the tumor microenvironment [58]. It is in the very context of 
shaping the tumor microenvironment landscape that epithelial-mesenchymal transition 
(EMT) [59], a critical phenotypic process that confers invasive and migratory capacity to 
localized primary tumor cells [60, 61] towards metastasis, has been implicated as a 
contributing force (under androgenic control) to prostate cancer development and 
progression. While androgens can induce EMT in prostate epithelial cells, low AR levels, 
conditions reflective of ADT, seem crucial in sensitizing prostate cancer cells to androgen-
mediated EMT [62]. EMT induces tumor stem cell-like properties [63], contributing to 
therapeutic resistance as well as evasion of apoptosis and immune surveillance [64]. While 
EMT involves a variety of interactive signaling pathways, transforming growth factor β 
(TGF-β) is recognized as the master orchestrator of this process, with hallmark 
consequences of loss of the cell adhesion molecule E-cadherin [65] (Fig. 1(F)). Rapidly 
growing evidence implicates EMT in human prostate cancer progression, with a significant 
association with poorer outcomes and aggressive disease [66, 67]. Since ADT has been 
shown to promote EMT, it may play an unorthodox role in fueling progression to lethal 
prostate cancer. ADT can significantly alter the dynamics of the prostate tumor 
microenvironment, affecting stromal, endothelial, and immune cells [68].
Prostate cancer has a lower proliferative capacity compared to other solid tumors, and this 
hallmark feature of growth kinetics renders apoptosis induction as a critical therapeutic 
avenue for targeted therapies directed at the apoptotic signaling mechanisms responsible for 
apoptosis evasion [69]. In the simplest terms, tumor progression results from an imbalance 
in cell proliferation and death. While resisting cell death is a classic hallmark of neoplasms 
[70], few compounds specifically targeting the apoptotic pathway have progressed in the 
developmental pipeline to phase III clinical studies in prostate cancer [71]. AR as a critical 
transcription factor in the regulation of prostate cell growth acts as a repressor for pro-
apoptotic genes; initiation of ADT triggers apoptotic cascades in hormone-sensitive prostate 
cancer cells and prostatic glandular epithelium [72]. In the subset of cells capable of evading 
apoptosis, the cellular machinery to activate the cascade is retained but severely altered. In 
the development of CRPC, molecular changes within prostate cancer cells may prevent the 
transcription of genes involved in the programmed cell death in castrate conditions [73]. 
Further, overexpression of Bcl-2, a protagonist antiapoptotic molecule belonging to the 
Bcl-2 family of proand antiapoptotic signaling effectors [74] (Fig. 1(G)), is associated with 
prostate cancer progression and confers resistance to ADT [75]. Bcl-2 has long attracted 
interest as a viable target in various tumors, most notably in the form of antisense 
oligonucleotides and small molecule inhibitors [76].
Anoikis describes a related modality of cell death, whereby cells undergo apoptosis upon 
detachment from the extracellular matrix (ECM), a process that must be evaded for tumor 
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cells to spread [77]. This is an essential tactic deployed by tumor cells as both a means of 
metastatic spread and therapeutic resistance. Tumor cells undergoing EMT are able to 
circumvent anoikis through cellular reprogramming; pro-EMT molecules including but not 
limited to transcriptional repressors SNAIL and SLUG, as well as cell adhesion molecules 
including E-cadherin, have been known to confer resistance to anoikis [78]. Furthermore, 
prostate cancer cells are able to alter their integrin expression profiles which leads to an 
anoikis-resistant phenotype. Integrin αvβ3 in prostate as well as other cancers confers a 
migratory phenotype and is overexpressed in the androgen-independent human prostate 
cancer cells (PC3) [79]. Regarded as a characteristic consequence and a necessary 
component to EMT, the processes of anoikis and EMT jointly contribute to the overall 
properties of chemoresistance, immune evasion, and metastasis.
Therapeutic Resistance in CRPC
The clinical landscape of CRPC has evolved rapidly, particularly in the past half decade. 
Patients today have FDA-approved options ranging from next-generation AR signaling 
inhibitors abiraterone and enzalutamide, taxanes docetaxel and cabazitaxel, bone targeting 
radiopharmaceutical radium-223, and dendritic cell vaccine sipuleucel-T, with additional 
promising therapeutics in the developmental pipeline. Despite the explosion of options, 
resistance to therapies in CRPC remains a critical area of unmet clinical need as evidenced 
by the modest survival benefits offered by each of these treatments. On top of the unknowns 
regarding optimal drug sequencing, the exact placement of drugs whose mechanisms of 
action do not involve the AR or AR signaling axis, namely radium-223 and sipuleucel-T, 
remains undetermined.
The mechanisms contributing to the emergence of CRPC likely continue in the castrate state 
as patients progress through additional lines of therapy. Instead of revisiting each of these 
mechanisms, this section will highlight findings on resistance to therapies administered for 
CRPC. Representative mechanisms are summarized in Table 1. In recent years, AR splice 
variants (AR-V) have been uncovered as a novel mechanism via which AR signaling is 
dynamically sustained in advanced lethal tumors. The AR-Vs are truncated forms of the AR 
lacking the LBD, some of which are constitutively active and allow for the ligand-
independent activation of AR target genes [92, 93]. The AR-V7, a clinically relevant variant 
due to its ligand-independent activity, along with abundance, heightened expression in 
CRPC tissues, and its detectable protein product has recently attracted interest as a potential 
therapy-selecting biomarker [94–96] (Fig. 1(H)). Preclinical [97, 98] as well as clinical 
evidence is suggestive of its role in resistance to novel AR-directed therapies abiraterone and 
enzalutamide [84••] but not to taxane chemotherapies [83••]. The differential response of 
AR-V7-positive patients to these two classes of therapy supports its use as a predictive 
biomarker, yet important details on the precise role of AR-Vs still need to be elucidated.
Even after the emergence of CRPC, the tumor microenvironment remains a remarkable 
contributor to tumor cell behavior at local and distal sites of invasion and metastasis. With a 
higher likelihood of tumor dissemination in the CRPC state, each compartment within which 
the tumor resides is a nurturing microenvironment—prostate, lymph node, bone, and so on. 
Notably, since approximately 90% [99] of patients with advanced disease develop 
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metastases to the bone, the leading cause of disease morbidity [100], there is great 
momentum in characterizing the bone microenvironment dynamics and the targeting of bone 
metastases in patients and in preclinical models towards overcoming therapeutic resistance. 
While not strictly a resistance mechanism in and of itself, tumor establishment in the bone 
niche is a known detriment to survival and quality of life [101, 102]. Interactions between 
tumor cells and resident cells of the bone microenvironment contribute to the development 
of bone metastases; tumor cells compete with hematopoietic stem cells (HSCs) for the 
occupation of the osteoblastic niche. Particularly, metastasis to the bone was promoted if the 
niche was altered in a way to eliminate HSCs from the bone microenvironment [103]. 
Clinically, denosumab, a human monoclonal antibody against receptor activator of NF-κB 
(RANK), ligand has been shown to delay the risk of skeletal complications in those with 
bone metastasis [104] as well as the development of bone metastatic disease in 
nonmetastatic CRPC [105]. RANK ligand, an active player in the bone microenvironment 
involved in normal bone turnover, has been shown to activate various transcription factors 
regulating EMT, stem cell properties, neuroendocrine differentiation, and osteomimicry, as 
well as promote bystander cell involvement in bone metastasis formation [106]. The 
radiopharmaceutical radium-223 offers improvement in overall survival, further lending 
support to the idea that the bone is a viable and important therapeutic target [107].
Resistance to Androgen Axis Inhibition/AR-Directed Therapies
Enzalutamide is a second-generation antiandrogen initially approved in 2012 for patients 
with mCRPC in the post-docetaxel setting, but its indication was later expanded in 2014 to 
include chemotherapy-naïve men with mCRPC [108]. Enzalutamide binds the LBD of the 
AR with high affinity, reducing AR nuclear translocation efficiency and disrupting binding 
to androgen response elements (AREs) on DNA, and impairs the recruitment of AR 
coactivators [109]. While the deployment of enzalutamide in clinical practice has 
significantly altered the treatment paradigm of CRPC, resistance is inevitable as evidenced 
by the modest improvement in overall survival. In addition, 25% of patients display primary 
resistance to the drug [110]. The missense mutation F876L in the LBD is known to confer 
resistance to enzalutamide by bestowing agonist properties [80••, 111], a common issue 
encountered with first-generation antiandrogens. Further, apalutamide (previously known as 
ARN-509), a newer second-generation antiandrogen, is also known to behave as an AR 
agonist in the presence of this mutation. Interestingly, there is evidence to suggest that 
mutants harboring F876L may respond to first-generation antiandrogens bicalutamide and 
flutamide [81]. Such findings may warrant clinical investigation of rechallenging certain 
patients with a previously failed agent. It also appears that GR induction, whose role is 
appreciated in the progression to CRPC, is a bypass mechanism that leads to transcription of 
AR-targeted genes and resistance to enzalutamide [112]. In the context of alternative AR 
activation, there is evidence that the aforementioned NF-κB pathway, particularly the 
upregulation of NF-κB2/p52, reactivates AR signaling through both full-length AR (AR-FL) 
and AR-V [82].
Abiraterone acetate is a selective potent inhibitor of CYP17 [113] approved in 2011 for 
mCRPC in the post-docetaxel setting, but with expanded indication in 2012 to include 
chemotherapy-naïve men with CRPC [114]. The efficacy of abiraterone reflects the 
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contribution of intratumoral and adrenal androgens in sustaining prostate cancer growth in 
CRPC. As with enzalutamide, resistance to abiraterone is inevitable and up to a third of 
patients display primary resistance [110]. Studies have revealed that several genes in 
androgen biosynthesis pathways, including CYP17A1, the primary target of abiraterone, are 
upregulated following treatment with abiraterone, representing an adaptation of tumors to 
evade the effects of inhibition [98]. Further, CYP17 inhibition results in the accumulation of 
upstream substrates, which may be utilized in alternative steroid biosynthesis pathways that 
ultimately lead to DHT [115]. Given the relatively recent approvals of both enzalutamide 
and abiraterone, much of their resistance mechanisms remain under exploration.
Resistance to Taxane Chemotherapies
Recent advances in genomic cloning and phosphoproteomic profiling of advanced prostate 
tumors have fueled great excitement in prostate cancer therapeutics towards the development 
and implementation of personalized targeted therapies [85, 116••, 117]. Nevertheless, the 
therapeutic impact of taxane-based first- and second-line chemotherapies (docetaxel and 
cabazitaxel, respectively) on patient survival is still essential in the management of advanced 
prostate cancer, both in hormonesensitive disease and CRPC [118••, 119••]. Docetaxel, first 
approved for CRPC in 2004, was the only chemotherapeutic drug to improve overall survival 
in patients with CRPC for the greater half of the following decade [120]. It is a microtubule-
targeting (stabilizing) agent that binds to β-tubulin subunits, resulting in apoptosis and G2/M 
cell cycle arrest [121, 122]. Microtubules are essential structures for facilitating AR 
trafficking to the nucleus [86, 123], and the activity of docetaxel significantly depletes 
nuclear AR [87]. In the CRPC setting, taxanes are an important therapeutic option for those 
refractory to AR-targeting agents, but resistance develops after a median PSA response 
duration of 7–8 months [14]. One well-documented mechanism of docetaxel resistance 
involves the overexpression of ATP-binding cassette (ABC) transporter molecules such as P-
glycoprotein contributing to increased drug efflux from the tumor cells [124]. Additionally, 
structural changes in β-tubulin, such as the class III β-tubulin isoform, can affect docetaxel 
binding and activity, diminishing docetaxel efficacy [88]. Notably, class III β-tubulin 
expression is heightened as a result of androgen ablation [125] and is predictive of response 
to docetaxel [126]. The former observation highlights the tumor’s ability to adapt to 
therapeutic interventions. Furthermore, docetaxel resistance is also associated with EMT 
induction, as evidenced by decreased E-cadherin expression and increased mesenchymal 
markers [90], reaffirming the significance of tumor microenvironment phenotypic landscape 
in therapeutic resistance.
Given the relatively shorter period since its approval, resistance mechanisms to cabazitaxel, 
a second-generation microtubule-stabilizing agent, are less understood. Mechanistically, it 
was recently demonstrated that while cabazitaxel does not result in the depletion of nuclear 
AR (as docetaxel), it reduces AR expression with the overall outcome of apoptosis [127]. 
Significantly enough, despite their similar targeting action against microtubules, the 
mechanisms of docetaxel and cabazitaxel resistance (dissected so far) are not entirely 
overlapping, implicating differential mechanisms of resistance. Thus, cabazitaxel has weaker 
affinity for P-glycoprotein, and it is less susceptible to resistance via drug efflux compared 
to docetaxel [91]. However, much like docetaxel, elevated class III β-tubulin and altered 
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EMT markers do confer resistance to cabazitaxel treatment in advanced tumors [89]. In the 
context of cross-resistance with antiandrogens, the therapeutic landscape becomes more 
intriguing as the action of cabazitaxel as a second-line chemotherapy is unhindered in 
enzalutamide-resistant prostate cancer, whereas docetaxel shows blunted efficacy [17]. 
Given that docetaxel is the standard first-line chemotherapy drug for CRPC and 
cabazitaxel’s performance in this setting is unknown, questions regarding sequencing 
remain, especially when coupled with implementation of AR-directed agents.
Considering the potential impact of transient interconversions of EMT to its reverse process 
mesenchymal-epithelial transition (MET) in the sequencing of taxane chemotherapy with 
antiandrogens to impair lethal prostate cancer, recent efforts focus on profiling the EMT 
phenotypic landscape towards building personalized signatures to predict therapeutic 
response/resistance in patients with advanced disease. As discussed above, microtubule-
targeting taxane chemotherapy offers a critical therapeutic avenue for those patients who 
have failed AR-targeting strategies. The detection of AR-V7 in clinical specimens has not 
been shown to predict resistance to taxanes [83••]; there is evidence that taxane 
chemotherapy may even contribute to the reversion of theAR-V7phenotype [128]. Further, 
recent work from our group provided exciting new evidence that in a preclinical model of 
prostate tumor progression, cabazitaxel treatment induces prostate tumor cell 
redifferentiation by reversing EMT to MET into the epithelial phenotype among therapy-
resistant prostate cancer cells [129]. Moreover, synergism of microtubule-targeting 
chemotherapy, docetaxel, with the novel AR N-terminal domain (NTD) inhibitor 
EPI-001/002, can navigate serial cycling of EMT to the reverse process of MET, supporting 
the possibility of reprogramming the EMT profile in advanced disease, even in those tumors 
harboring the AR variants [130]. Despite its temporal nature, the plasticity of EMT emerges 
as an attractive target for resensitizing prostate tumors resistant to AR-directed therapies 
and/or first- or second-line microtubule-targeting chemotherapies.
The Future of Clinical Management of Advanced CRPC
Apparent from both the non-therapy-specific and therapy-specific mechanisms of resistance 
in CRPC, tumor cells display remarkable adaptability. The clinical heterogeneity in disease 
course is a reflection of the marked molecular heterogeneity observed in prostate cancer, 
demanding a personalized approach to treatment [131]. Newer techniques of noninvasive 
liquid biopsies including circulating tumor cells (CTCs) and circulating tumor DNA 
(ctDNA) provide opportunities to examine tumor adaptations in real time and has profound 
implications for precision medicine [132]. Significantly enough, liquid biopsies allow 
prostate cancer to be followed temporally to identify resistant clones and driver mutations 
that may account for therapeutic failure [116••]. As we become better acquainted with the 
underlying molecular mechanisms that drive resistance and associated biomarkers, serial 
biopsies are likely to provide additional insights into clinical decision-making.
Evidence from a series of combination approaches assessing the clinical benefit, including 
abiraterone and enzalutamide, NCT01949337; Rad-223 and abiraterone, NCT02043678; 
enzalutamide and docetaxel, NCT01565928, among many others, provides promise as to the 
therapeutic sequencing of existing combination strategies. Particularly, with the heightened 
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interest surrounding immunotherapies, combination strategies involving sipuleucel-T are 
being considered as well for additive clinical benefits. For example, the potential approach 
of combining sipuleucel-T and abiraterone, drugs with nonoverlapping toxicities, may 
overcome the initial lag in objective clinical benefit often seen in sipuleucel-T monotherapy 
[133]. In metastatic androgen-sensitive disease, the combination of docetaxel and ADT has 
provided a significant survival advantage over ADT alone and is considered the standard of 
care today [118••]. Considering that certain therapies together may have synergistic effects 
preclinically [130], the shift towards strategic combination therapies for CRPC in the future 
is certainly possible as well [134]. Preclinical and early clinical studies reveal promising 
leads in novel therapeutic targets. A recent phase II study involving the PARP inhibitor 
olaparib benefitted men with advanced CRPC harboring DNA repair mutations [135], which 
occur at a frequency of 11.8% in patients with mCRPC [136]. These findings point at not 
only a potential biomarker for treatment selection but also a therapeutic target in those who 
have failed multiple lines of therapy. In the context of the tumor microenvironment, the 
process of EMT is a potential target, given the relevance of EMT-to-MET cycling. TGF-β 
inhibition necessitates a cautious undertaking due to its ubiquity and complex intersecting 
signaling pathways but stands to open an alternative avenue to overcoming therapeutic 
resistance to currently employed antiandrogen and taxane-based strategies [137], potentially 
in the appropriately designed sequencing approach. Galunisertib (LY2157299), a small 
molecule inhibitor targeting TGF-β receptor I, biologically impacting the EMT outcomes in 
prostatic tumors is currently being investigated alongside enzalutamide (NCT02452008) in a 
phase II study as well in preclinical models of advanced tumor progression to metastasis.
Conclusions
The seemingly simple reliance of prostate cells on androgens belies the complexities that 
arise in advanced prostate cancer, all of which directly reflect the intricacies of the 
mechanisms of resistance responsible for therapy failure in patients. Critically, further tumor 
adaptations arise in the CRPC state driven by the specific selective pressures of next-
generation AR-directed therapies and cytotoxic chemotherapies, many of which were 
unknown until recently. Promisingly, however, resistance to these interventions may be 
reversible by employing strategies such as EMT-to-MET cycling, yet our understanding of 
how to optimize such synergism between preexisting and newer therapeutics is still limited. 
Clinical management of advanced CRPC is challenging due to the diversity of resistant 
clones, especially in those refractory to multiple lines of therapies. The future of prostate 
cancer management in these patients will likely involve not only serial liquid biopsies to 
assess disease state and probe for additional actionable targets but also strategic combination 
strategies that induce reversal of the resistant phenotype. Ongoing studies on not only newer 
therapeutic targets but also novel combination strategies will be crucial in controlling the 
dynamic process of tumor clone evolution and prolonging survival in lethal prostate cancer.
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Fig. 1. 
Major mechanisms of therapeutic resistance to androgen axis-targeting therapies in prostate 
cancer. A AR gene and mRNA amplifications to increase ligand sensitivity. B Utilization of 
nonandrogen ligands such as estradiol and glucocorticoids. C AR activation via alternative 
survival signaling pathways including PI3K/AKT, NF-κB, and RTKs. D AR coactivators can 
enhance AR sensitivity to various alternative ligands. E Utilization of alternative ligand 
synthesis pathways for conversion of adrenal androgen precursors. F Activation of TGF-β 
signaling pathway in EMT-to-MET interconversions. G Overexpression of prosurvival 
molecules such as Bcl-2 contributing to evasion of apoptosis activation. H AR splice variants 
with ligand-independent activation promote AR transcriptional programs in the absence of 
ligand
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Table 1
Drug-specific mechanisms of resistance in CRPC therapy. Notably, non-drug-specific mechanisms driving the 
development of hormone refractory disease continue to play a role in disease progression in CRPC
Drug-specific mechanism(s) of resistance
Enzalutamide • F876L missense mutation [80••, 81]
• GR induction [82]
• AR splice variants [83••]
Abiraterone • CYP17A1 upregulation [84••]
• Alternative ligand synthesis [85]
• AR splice variants [83••]
Docetaxel • Increased drug efflux [86]
• Heightened class III β-tubulin expression [87]
• EMT [88]
• AR variants [89]
Cabazitaxel • Heightened class III β-tubulin expression [90]
• EMT [91]
• Nuclear AR [91]
Sipuleucel-T • Undetermined
Radium-223 • Undetermined
Apalutamide • F876L missense mutation [80••, 81]
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